KR20090116707A - 니코틴성 아세틸콜린 수용체 조절자 - Google Patents

니코틴성 아세틸콜린 수용체 조절자 Download PDF

Info

Publication number
KR20090116707A
KR20090116707A KR1020097014828A KR20097014828A KR20090116707A KR 20090116707 A KR20090116707 A KR 20090116707A KR 1020097014828 A KR1020097014828 A KR 1020097014828A KR 20097014828 A KR20097014828 A KR 20097014828A KR 20090116707 A KR20090116707 A KR 20090116707A
Authority
KR
South Korea
Prior art keywords
mmol
pyrazol
alkyl
phenyl
added
Prior art date
Application number
KR1020097014828A
Other languages
English (en)
Korean (ko)
Inventor
키아라 기론
아리안나 넨치니
이올란다 미코
리카르도 자날레티
라우라 마카리
헨드리크 보트만
사이먼 헤이더
마우리치오 바로네
카르멜라 프라텔리
보이드 해리슨
Original Assignee
시에나 바이오테크 에스.피.에이.
와이어쓰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시에나 바이오테크 에스.피.에이., 와이어쓰 filed Critical 시에나 바이오테크 에스.피.에이.
Publication of KR20090116707A publication Critical patent/KR20090116707A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
KR1020097014828A 2007-01-16 2008-01-16 니코틴성 아세틸콜린 수용체 조절자 KR20090116707A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88062907P 2007-01-16 2007-01-16
US60/880,629 2007-01-16

Publications (1)

Publication Number Publication Date
KR20090116707A true KR20090116707A (ko) 2009-11-11

Family

ID=39345157

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097014828A KR20090116707A (ko) 2007-01-16 2008-01-16 니코틴성 아세틸콜린 수용체 조절자

Country Status (25)

Country Link
US (1) US8163729B2 (US08163729-20120424-C00306.png)
EP (1) EP2118067B1 (US08163729-20120424-C00306.png)
JP (1) JP2010515770A (US08163729-20120424-C00306.png)
KR (1) KR20090116707A (US08163729-20120424-C00306.png)
CN (1) CN101679287B (US08163729-20120424-C00306.png)
AR (1) AR064921A1 (US08163729-20120424-C00306.png)
AU (1) AU2008206759B2 (US08163729-20120424-C00306.png)
BR (1) BRPI0806665A2 (US08163729-20120424-C00306.png)
CA (1) CA2675676A1 (US08163729-20120424-C00306.png)
CL (1) CL2008000119A1 (US08163729-20120424-C00306.png)
CO (1) CO6351782A2 (US08163729-20120424-C00306.png)
CR (1) CR10930A (US08163729-20120424-C00306.png)
EA (1) EA016948B1 (US08163729-20120424-C00306.png)
EC (1) ECSP099490A (US08163729-20120424-C00306.png)
HK (1) HK1142335A1 (US08163729-20120424-C00306.png)
IL (1) IL199889A0 (US08163729-20120424-C00306.png)
MX (1) MX2009007615A (US08163729-20120424-C00306.png)
NZ (1) NZ578411A (US08163729-20120424-C00306.png)
PA (1) PA8766201A1 (US08163729-20120424-C00306.png)
SA (1) SA08290018B1 (US08163729-20120424-C00306.png)
SV (1) SV2009003334A (US08163729-20120424-C00306.png)
TW (1) TW200901974A (US08163729-20120424-C00306.png)
UA (1) UA98317C2 (US08163729-20120424-C00306.png)
WO (1) WO2008087529A1 (US08163729-20120424-C00306.png)
ZA (1) ZA200904943B (US08163729-20120424-C00306.png)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
WO2009091813A1 (en) * 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
WO2009091832A1 (en) * 2008-01-14 2009-07-23 Wyeth Synthesis of pyrazoles
US20090181953A1 (en) * 2008-01-14 2009-07-16 Wyeth Compound forms and uses thereof
TW201004941A (en) * 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
BRPI0917819B8 (pt) 2008-08-22 2021-05-25 Baxalta GmbH compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado
WO2010104843A2 (en) * 2009-03-09 2010-09-16 The Regents Of The University Of California Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
EP2959902A1 (en) * 2009-07-23 2015-12-30 Novartis AG Use of azabicycloalkyl derivatives for the treatment or prevention of ataxia
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
UA113501C2 (uk) * 2010-11-03 2017-02-10 Пестицидні композиції і пов'язані з ними способи
CA2813451A1 (en) * 2010-11-18 2012-05-24 Dignity Health Methods of diagnosing and treating neurodegenerative diseases
KR20150064098A (ko) * 2012-10-02 2015-06-10 다이닛본 스미토모 세이야꾸 가부시끼가이샤 이미다졸 유도체
CN105254564A (zh) * 2015-10-31 2016-01-20 丁玉琴 一种2-甲基-3,4-二硝基-5-(甲氧苯基)吡唑的合成方法
CN105646358B (zh) * 2016-03-01 2018-03-09 苏州艾缇克药物化学有限公司 一种3‑氨基‑5‑(4‑甲氧苯基)吡唑的合成方法
CN112480079B (zh) * 2017-11-08 2022-03-11 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
PE20201068A1 (es) 2018-04-04 2020-10-19 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos
GB202006382D0 (en) 2020-04-30 2020-06-17 Spermatech As Use
CN113925606B (zh) * 2021-10-25 2023-07-07 四川大学华西医院 一种神经调控导航定位方法、装置和神经调控治疗系统

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU167263B (US08163729-20120424-C00306.png) 1973-02-12 1975-09-27
DE2527677A1 (de) * 1975-06-21 1977-01-20 Bayer Ag Verfahren zur herstellung von 2,4- dioxo-1,2,3,4-tetrahydro-s-triazino- eckige klammer auf 1,2-a eckige klammer zu -benzimidazolen
US4665183A (en) 1985-12-20 1987-05-12 American Home Products Corp. Process for preparing 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof useful for the treatment of cognitive impairments
US4624954A (en) 1985-12-20 1986-11-25 American Home Products Corporation 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof, useful for the treatment of cognitive impairments
US5219857A (en) 1986-10-16 1993-06-15 American Cyanamid Company Method of treating cognitive and related neural behavioral problems
US4904658A (en) 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5260331A (en) 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
US5422355A (en) 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
FR2655988B1 (fr) * 1989-12-20 1994-05-20 Adir Cie Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IE911774A1 (en) 1990-06-11 1991-12-18 Akzo Nv Pyridinylpiperazine derivatives
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
US5622976A (en) 1991-12-31 1997-04-22 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
JPH0616638A (ja) 1992-03-30 1994-01-25 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物およびその医薬用途
DE69333299T2 (de) 1992-07-24 2004-09-09 The Regents Of The University Of California, Oakland Arzneimittel die den durch AMPA Rezeptoren vermittelten synaptischen Response erhöhen
DK0674641T3 (da) 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
EP0674631B1 (en) 1992-12-17 1999-12-08 Pfizer Inc. Substituted pyrazoles as crf antagonists
EP0674624B1 (en) 1992-12-17 1999-01-20 Pfizer Inc. Pyrazoles having crf antagonist activity
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
JP3426242B2 (ja) 1994-01-14 2003-07-14 株式会社アズウェル ジアザシクロアルカンアルキルスルホンアミド誘導体
JP3319651B2 (ja) * 1994-04-26 2002-09-03 富士写真フイルム株式会社 感光性転写シート
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
US6288091B1 (en) * 1995-12-29 2001-09-11 Boehringer Ingelheim Ltd. Antiherpes virus compounds and methods for their preparation and use
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
WO1997043262A1 (en) 1996-05-11 1997-11-20 Smithkline Beecham P.L.C. Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
GB9708694D0 (en) 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
US6329368B1 (en) * 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
KR100247563B1 (ko) 1997-07-16 2000-04-01 박영구 키랄3,4-에폭시부티르산및이의염의제조방법
NZ502252A (en) * 1997-07-25 2001-09-28 H Indole and 2,3-dihydroindole derivatives useful for inhibiting serotonin reuptake and antagonism of 5-HT1a receptors
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
MXPA00009569A (es) 1998-03-31 2002-08-06 Acadia Pharm Inc Compuestos con actividad en receptores muscarinicos.
US6124278A (en) 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
DK1083889T3 (da) 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
US6677333B1 (en) * 1999-01-26 2004-01-13 Ono Pharmaceutical Co., Ltd. 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
US20010044445A1 (en) * 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
AU1161601A (en) 1999-11-05 2001-05-14 University College London Activators of soluble guanylate cyclase
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
HUP0300359A2 (hu) * 2000-02-07 2003-06-28 Abbott Gmbh & Co. Kg. 2-Benzotiazolil-karbamid-származékok és protein kináz inhibitorként történő felhasználásuk és ezeket tartalmazó gyógyszerkészítmények
ES2286114T3 (es) 2000-03-31 2007-12-01 Ortho-Mcneil Pharmaceutical, Inc. Imidazopiridina fenil-substituidos.
DE60138605D1 (de) 2000-03-31 2009-06-18 Ortho Mcneil Pharm Inc Phenyl-substituierte indole als h3 histaminrezeptorantagonisten
MXPA02010029A (es) 2000-04-10 2003-02-12 Pfizer Prod Inc Compuestos de benzamido-piperidina como antagonistas de la sustancia p.
US6448276B1 (en) 2000-05-17 2002-09-10 Inspire Pharmaceuticals, Inc. Method for treating vaginal dryness with nicotinic acetylcholine receptor agonists
US6638950B2 (en) 2000-06-21 2003-10-28 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
JP2002030073A (ja) 2000-07-19 2002-01-29 Ono Pharmaceut Co Ltd ４−（３−（４−モルホリノブチリルアミノ）フェニル）−２ｈ−フタラジン−１−オン・メタンスルホン酸塩・１水和物およびその製造方法。
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
IL145209A0 (en) * 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
WO2002024694A1 (en) 2000-09-22 2002-03-28 Smithkline Beecham, P.L.C. Pyrazolopyridines and pyrazolopyridazines as antidiabetics
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
DE60121032T2 (de) 2000-12-13 2007-01-11 Wyeth Heterocyclische sulfonamide als inhibitoren der beta-amyloid-produktion
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
MXPA03006843A (es) 2001-02-16 2003-11-13 Aventis Pharma Inc Derivados heterociclicos novedosos de ureas y su uso como ligandos para receptor d3 de dopamina.
EP1935887B1 (en) 2001-02-16 2010-01-13 Aventis Pharmaceuticals, Inc. Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0103987A3 (en) 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
KR100579813B1 (ko) 2001-10-16 2006-05-12 주식회사 에스티씨나라 피페리딘 유도체, 이의 제조방법 및 이를 포함하는 치매치료용 약학적 조성물
NZ534712A (en) 2002-02-19 2006-11-30 Ono Pharmaceutical Co Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
UA77814C2 (en) 2002-07-03 2007-01-15 Lundbeck & Co As H Spirocyclic piperidines as antagonists of mch1 and use thereof
WO2004007459A2 (en) * 2002-07-12 2004-01-22 Janssen Pharmaceutica N.V. Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor
GB0216233D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
TW200401641A (en) 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
AU2003253686A1 (en) 2002-08-01 2004-02-23 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
TWI334868B (en) * 2003-06-03 2010-12-21 Nippon Kayaku Kk [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof
EP1648904B1 (en) 2003-07-31 2007-08-22 Wyeth N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
EP1713809B1 (en) 2004-02-04 2009-07-29 Neurosearch A/S Dimeric azacyclic compounds and their use
WO2005085257A1 (en) 2004-03-02 2005-09-15 Wyeth Macrolides and methods for producing same
AU2005219389A1 (en) 2004-03-02 2005-09-15 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
KR20070026811A (ko) * 2004-06-16 2007-03-08 와이어쓰 베타-세크리타제 억제제로서의 디페닐이미다조피리미딘 및디페닐이미다졸 아민
MXPA06014793A (es) 2004-06-16 2007-02-16 Wyeth Corp Derivados de amino-5, 5-difenilimidazolona para la inhibicion de ??-secretasa.
ZA200700527B (en) * 2004-07-20 2008-08-27 Siena Biotech Spa Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
US20060063930A1 (en) 2004-08-20 2006-03-23 Agoston Gregory E Compositions and methods comprising proteinase activated receptor antagonists
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
EP1853573A1 (en) 2005-02-25 2007-11-14 Rigel Pharmaceuticals, Inc. Benzisothiazoles useful for treating or preventing hcv infection
US20090181852A1 (en) * 2005-11-15 2009-07-16 Inverness Medical Switerland Gmbh Assays
WO2007098826A2 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
GB0723815D0 (en) 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
US20090181953A1 (en) * 2008-01-14 2009-07-16 Wyeth Compound forms and uses thereof
WO2009091832A1 (en) 2008-01-14 2009-07-23 Wyeth Synthesis of pyrazoles
TW201004941A (en) * 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
US20100016360A1 (en) * 2008-07-16 2010-01-21 Wyeth Alpha7 nicotinic acetylcholine receptor inhibitors
US20100016598A1 (en) * 2008-07-16 2010-01-21 Wyeth Alpha7 nicotinic acetylcholine receptor inhibitors
US20100016343A1 (en) * 2008-07-16 2010-01-21 Wyeth Alpha7 nicotinic acetylcholine receptor inhibitors

Also Published As

Publication number Publication date
EA016948B1 (ru) 2012-08-30
CO6351782A2 (es) 2011-12-20
CN101679287B (zh) 2013-03-27
ECSP099490A (es) 2009-09-29
CL2008000119A1 (es) 2008-05-16
JP2010515770A (ja) 2010-05-13
IL199889A0 (en) 2010-04-15
WO2008087529A1 (en) 2008-07-24
CR10930A (es) 2013-02-12
UA98317C2 (ru) 2012-05-10
AU2008206759B2 (en) 2013-09-05
PA8766201A1 (es) 2008-11-19
SA08290018B1 (ar) 2013-01-17
MX2009007615A (es) 2009-07-27
AR064921A1 (es) 2009-05-06
CA2675676A1 (en) 2008-07-24
EP2118067A1 (en) 2009-11-18
US20100029606A1 (en) 2010-02-04
NZ578411A (en) 2011-06-30
EP2118067B1 (en) 2013-05-08
HK1142335A1 (en) 2010-12-03
ZA200904943B (en) 2010-09-29
SV2009003334A (es) 2010-08-09
BRPI0806665A2 (pt) 2011-09-06
AU2008206759A1 (en) 2008-07-24
EA200900831A1 (ru) 2010-02-26
CN101679287A (zh) 2010-03-24
US8163729B2 (en) 2012-04-24
TW200901974A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
KR20090116707A (ko) 니코틴성 아세틸콜린 수용체 조절자
JP2011528372A (ja) α７ニコチン性アセチルコリンレセプターインヒビター
JP4208925B2 (ja) 治療薬
JP4632544B2 (ja) アミノピラゾール誘導体
JP4176805B2 (ja) 肥満の処置のためのピロール−３−カルボキサミド誘導体
JP5207983B2 (ja) 肥満および他のｃｎｓ障害を治療するためのピラゾール類
JP5850589B2 (ja) フェニル−３−アザ−ビシクロ［３．１．０］ヘキサ−３−イル−メタノン及び薬物としてのこれらの使用
JP4177435B2 (ja) 治療薬
JP2008525404A (ja) 治療剤
TW201125854A (en) 5-membered heterocycle-based p38 kinase inhibitors
JP4740116B2 (ja) 精神疾患および神経障害の処置のための５−ｈｔ受容体アンタゴニスト
JP2005521651A (ja) ピロリドンカルボキサミド類
JPH0873439A (ja) １−ベンジル−１，３−ジヒドロ−２ｈ−ベンズイミダゾール−２−オン誘導体、これらの調製およびこれらを含有する薬学的組成物
US20100016598A1 (en) Alpha7 nicotinic acetylcholine receptor inhibitors
JP2011500728A (ja) 疾患の処置に有用なニコチン性アセチルコリン受容体の（１，４−ジアザ−ビシクロ［３．２．２］ノン−６−エン−４−イル）−ヘテロシクリル−メタノンリガンド
JP2002534418A (ja) ＧＡＢＡ−Ａα５受容体のリガンドとしてのテトラヒドロインダゾール誘導体
US20100016343A1 (en) Alpha7 nicotinic acetylcholine receptor inhibitors
JP2011518800A (ja) Ｃｂ１アンタゴニスト活性を有する（５ｒ）−１，５−ジアリール−４，５−ジヒドロ−１ｈ−ピラゾール−３−カルボキシアミジン誘導体
CA2688208A1 (en) 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application